Table 5.
Influence of candidate genes on response to rheumatoid arthritis for patients receiving etanercept (ETA), infliximab (INF), or adalimumab (ADA) therapy
| Candidate gene(s) | Sample size | Response criteria | Follow-up time | Genotype/phenotype correlation | Ref. |
|---|---|---|---|---|---|
| TNF-α (−238G>A) | 40 | DAS28 | 6 months | GA genotype is associated with a negative response to INF | 169 |
| TNF-α (−857) | 70 | ACR20 | 3 months | CT/TT genotypes are associated with positive response to ETA | 170 |
| 58 | DAS28 | N/A | CC genotype is associated with positive response to INF | 171 | |
| TNFRII 676T>G | 105 | ACR20 | 12 months | TG genotype is associated with a negative response to ETN, INF or ADA | 172 |
| 58 | DAS28 | N/A | TT genotype is associated with positive response in RA | 171 | |
| FCGR3A 158F>V | 91 | ACR20 | 7.5 months | FF genotype is associated with a positive response to INF | 173 |
| TNF-α (−308G>A) & IL-10 (−1087G>A) combination | 123 | ACR20, DAS28 | 3 months | GG genotype is associated with positive response to ETA | 174 |
| IL-1RN VNTR and TGFB1 915G>C Combination | 123 | ACR20, DAS28 | 3 months | A2/C allele combination is associated with negative response to ETA | 174 |
| HLA-DRB1 | 255 | ACR50 | 12 months | *0404 & *0101 combination is associated with positive response | 175 |
| IL-10 | 50 | DAS28 | 48 months | IL-10.R3 is associated with positive response | 176 |
| 50 | DAS28 | 48 months | IL-10.G13 is associated with moderate or negative response | ||
| 50 | DAS28 | 48 months | IL-10.R2 & G13 combination is associated with moderate or negative response | ||
| 50 | DAS28 | 48 months | IL-10.R3 & G9 combination is associated with positive response |
Abbreviations: ACR, American College of Rheumatology based on perceptual improvement (20, 50, 70, 90%) in disease symptoms; DAS28, disease activity score in 28 joints; IL, interleukin; TNF-α, tumor necrosis factor-α.